GB995338A - Polysaccharides and methods for their production - Google Patents
Polysaccharides and methods for their productionInfo
- Publication number
- GB995338A GB995338A GB3719263A GB3719263A GB995338A GB 995338 A GB995338 A GB 995338A GB 3719263 A GB3719263 A GB 3719263A GB 3719263 A GB3719263 A GB 3719263A GB 995338 A GB995338 A GB 995338A
- Authority
- GB
- United Kingdom
- Prior art keywords
- polysaccharide
- aqueous solution
- acid
- staphylococcus aureus
- chloroacetic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
Abstract
In a process for the production of a staphylococcal antigen product, intact cells of a strain of Staphylococcus aureus identifiable by the property of forming loosely-cohesive, diffuse, semi-opaque colonies when grown in a semi-solid or soft agar culture medium containing plasma, serum or protein components thereof, are reacted with an aqueous acid at a pH of not more than 4 and the resulting aqueous solution containing an immunogenic polysaccharide is separated from insoluble solid material, the aqueous solution, upon adjustment to a pH acceptable for injection, being capable of stimulating the formation of a protective anti-body against Staphylococcus aureus. Specified Staphyloccus aureus strains are UC76, Smith, S193N4, H & D, Castellani, MCD138, SK4473, K6, K93 and K93M. The intact cells may be live or "killed" by e.g. heat-treatment, or treatment with phenol or b -propiolactone. The acid reactant may be e.g. aqueous acetic, formic, propionic, mono-chloroacetic, tri-chloroacetic or hydrochloric acids. The aqueous solution of polysaccharide, after separation from solids, may be used as a vaccine, the pH being adjusted to one suitable for parenteral injection, e.g. pH 6-8. The vaccine may be made isotonic by addition of sodium chloride and sterilized by heat, ultra-violet irradiation, or by addition of a preservative such as phenol, thimerosol or benzethonium chloride. Alternatively, the polysaccharide may be isolated from its aqueous solution by e.g. dialysis and freeze-drying, and may be purified by e.g. chromatography, precipitation of impurities, or by formation of a quaternary ammonium complex. The polysaccharide contains carboxyl groups and may be obtained as free acid, or in the form of sodium, potassium, calcium, magnesium, ammonium or amine salts. In examples, cultures of the UC76 strain of Staphylococcus aureus are treated with 0.1N acetic acid at 100 DEG C., 1N and 0.1N acetic acid at 121 DEG C. and tri-chloroacetic acid at room temperature. The extracted polysaccharide resembles in properties polysaccharide II disclosed in the parent Specification.ALSO:In a process for the production of a staphylococcal antigen product, intact cells of a strain of staphylococcus aureus identifiable by the property of forming loosely-cohesive, diffuse, semi-opaque colonies when grown in a semi-solid or soft agar culture medium containing plasma, serum or protein components thereof, are reacted with an aqueous acid at a pH of not more than 4 and the resulting aqueous solution containing an immunogenic polysaccharide is separated from insoluble solid material, the aqueous solution, upon adjustment to a pH acceptable for injection, being capable of stimulating the formation of a protective antibody against staphylococcus aureus. Specified staphylococcus aureus strains are UC76, Smith, S 193N4, H & D, Castellani, MCD138, SK4473, K6, K93 and K93M. The intact cells may be live or "killed" by e.g. heat-treatment, or treatment with phenol or b -propiolactone. The acid reactant may be, e.g., aqueous acetic, formic, propionic, monochloroacetic, tri-chloroacetic or hydrochloric acids. The aqueous solution of polysaccharide, after separation from solids, may be used as a vaccine, the pH being adjusted to one suitable for parenteral injection, e.g. pH 6-8. The vaccine may be made isotonic by addition of sodium chloride and sterilized by heat, ultra-violet irradiation, or by addition of a preservative such as phenol, thimerosol or benzethonium chloride. Alternatively, the polysaccharide may be isolated from its aqueous solution by, e.g. dialysis and freeze-drying, and may be purified by, e.g. chromatography, precipitation of impurities, or by formation of a quaternary ammonium complex. The polysaccharide contains carboxyl groups and may be obtained as free acid, or in the form of sodium, potassium, calcium, magnesium, ammonium or amine salts. In examples, cultures of the UC76 strain of staphylococcus aureus are treated with 0,1N acetic acid at 100 DEG C., IN and 0,1N acetic acid at 121 DEG C., and tri-chloroacetic acid at room temperature. The extracted polysaccharide resembles in properties polysaccharide II disclosed in the parent Specification.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB3719263A GB995338A (en) | 1963-09-20 | 1963-09-20 | Polysaccharides and methods for their production |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB3719263A GB995338A (en) | 1963-09-20 | 1963-09-20 | Polysaccharides and methods for their production |
Publications (1)
Publication Number | Publication Date |
---|---|
GB995338A true GB995338A (en) | 1965-06-16 |
Family
ID=10394531
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB3719263A Expired GB995338A (en) | 1963-09-20 | 1963-09-20 | Polysaccharides and methods for their production |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB995338A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2468372A1 (en) * | 1977-09-30 | 1981-05-08 | Yoshida Kosaku | NEW VACCINE AGAINST INFECTIOUS DISEASES IN BOVINE AND METHOD OF PRODUCING THE SAME |
US20120282295A1 (en) * | 2009-10-30 | 2012-11-08 | Novartis Ag | Purification of staphylococcus aureus type 5 and type 8 capsular saccharides |
-
1963
- 1963-09-20 GB GB3719263A patent/GB995338A/en not_active Expired
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2468372A1 (en) * | 1977-09-30 | 1981-05-08 | Yoshida Kosaku | NEW VACCINE AGAINST INFECTIOUS DISEASES IN BOVINE AND METHOD OF PRODUCING THE SAME |
US20120282295A1 (en) * | 2009-10-30 | 2012-11-08 | Novartis Ag | Purification of staphylococcus aureus type 5 and type 8 capsular saccharides |
US9060965B2 (en) * | 2009-10-30 | 2015-06-23 | Glaxosmithkline Biologicals Sa | Purification of Staphylococcus aureus type 5 capsular saccharides |
US9441004B2 (en) | 2009-10-30 | 2016-09-13 | Glaxosmithkline Biologicals Sa | Purification of staphylococcus aureus type 8 capsular saccharides |
EP2493498B1 (en) | 2009-10-30 | 2017-03-22 | GlaxoSmithKline Biologicals SA | Purification of staphylococcus aureus type 5 and type 8 capsular saccharides |
US11208424B2 (en) | 2009-10-30 | 2021-12-28 | Glaxosmithkline Biologicals Sa | Staphylococcus aureus type 5 capsular saccharides |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3396081A (en) | Hyaluronic acid preparation and method of producing same | |
FI79024C (en) | Process for the preparation of Haemophilus influenzae b-polysaccharide xotoxoid conjugate vaccine. | |
US4460575A (en) | Vaccinal complex containing a specific antigen and vaccine containing it | |
EP0530173B1 (en) | Method for inactivating prions | |
GB1473541A (en) | Vaccines processes for preparing the same applications thereof and hyperimmune sera prepared therefrom | |
Walker | A method for the isolation of toxic and immunizing fractions from bacteria of the Salmonella group | |
Lambden et al. | Synthesis of immunogenic oligosaccharide-protein conjugates from the lipopolyasaccharide of Neisseria Gonorrhoeae P9 | |
GB995338A (en) | Polysaccharides and methods for their production | |
US3936351A (en) | Method for preparing glucoronyl-glucosamino-glycan sulphates exhibiting antilipasaemic activity | |
DE1617397C3 (en) | Production of a tumor static agent by growing Streptococcus haemolyticus | |
GB979275A (en) | A method of preparing polypeptide substance having antiphlogistic properties | |
US2787576A (en) | Attenuating b. abortus and p. multocida | |
CH423095A (en) | Process for the manufacture of a rabies vaccine | |
EP0298991B1 (en) | Novel lectins derived from bacterial pili | |
US4110434A (en) | Novel immunological adjuvants, process for their production and compositions containing them | |
US3185624A (en) | Preparation of purified lipid a from crude lipid a derived from lipopolysaccharides of gram-negative bacteria | |
Pillemer et al. | Separation and immunologic evaluation of soluble pertussal antigens | |
JPS58129001A (en) | Novel immunoligically active polyglucide and its preparation | |
Kanazawa et al. | Pure culture of the pathogenic agent of Tyzzer's disease of mice | |
US3627642A (en) | Lysozyme salts | |
GB1060513A (en) | Process for the preparation of glucuronoglycosaminoglycan hyaluronate lyase | |
IL29925A (en) | Tetanus vaccine and process for preparing it | |
Kawakami et al. | EXPERIMENTAL SALMONELLOSIS III: New Toxic Fraction (L) Obtained from Salmonella enteritidis and Its Immunological Properties | |
Kanamaru et al. | Production of acid heteropolysaccharides from n-paraffine | |
FI60576B (en) | FOERFARANDE FOER FRAMSTAELLNING AV LYSOZYM |